Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

Inclusion Criteria: 1. Age 40-75 years 2. Low to Intermediate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using pooled cohort equations (PCE). 3. Coronary CT angiography shows atherosclerotic plaque in the main coronary vessels (\>2mm diameter) with luminal stenosis \<70% Exclusion Criteria: 1. Combination with serious cardiovascular diseases, including 1. Heart failure (ejection fraction \<30%) 2. Arrhythmias (persistent atrial flutter/atrial fibrillation, second-degree or third-degree atrioventricular block) 3. Hemodynamically important valvular disease 4. Hemodynamically important congenital heart disease 5. Stroke 2. Myocardial infarction, coronary revascularization, or severe/unstable angina before or within 1 month of screening 3. Active liver disease or hepatic dysfunction (defined as alanine aminotransferase or aspartate aminotransferase\> 3 times the upper limit of normal) 4. Unexplained creatine phosphokinase\> 6 times the upper limit of normal 5. Nephrotic syndrome 6. Diabetes mellitus 7. Uncontrollable hypertension 8. Uncontrollable hypothyroidism 9. Hypersensitivity to statins 10. Any planned surgical procedure for the treatment of atherosclerosis 11. Gastrointestinal diseases affecting drug absorption or history of gastrointestinal surgery 12. Survival-limiting diseases 13. Concurrent long-term immunosuppressive therapy 14. Participation in another clinical trial concurrently or within 30 days before screening 15. Pregnant or breastfeeding 16. Other unsuitable situations deemed by physicians